Abstract 239P
Background
Comorbidities are common among breast cancer patients, including chronic and preexisting conditions or even treatment sequelae. These may seriously affect patients’ overall health and quality of life. Identification of potential correlations could help improve clinical practice and cancer patients’ care.
Methods
Breast cancer patients using the CareAcross personalised and multilingual online support platforms report cancer characteristics such as metastatic, hormonal receptor (HR) and HER2 status; additionally, some report comorbid conditions (diabetes, anaemia, hypertension and others). Among all inputs collected retrospectively, the subset of data from patients from 5 European countries (UK, Germany, France, Spain and Italy) who reported cancer characteristics as well as comorbidities was selected and analysed in January 2022 to identify potential correlations.
Results
Data was collected from 4902 respondents: 618 (12.6%) had metastatic and 4284 (87.4%) non-metastatic cancer; 3452 patients reported hormonal status (77.0% of whom as HR+ and 23.0% as HR-); 2833 stated HER2 diagnosis (35.3% of whom as HER2+ and 64.7% as HER2-). Incidence of diabetes was statistically significantly higher in patients with metastatic cancer (4.7% vs 2.9% for non-metastatic), and patients with HER2+ (3.5% vs 2.1% with HER2-); p<0.05. Anaemia was statistically significantly lower (p<0.05) in HR+ (6.1%) vs HR- patients (8.1%). In contrast, hypertension was higher in HR+ patients (11.5%) compared to HR- (9.1%); p=.053. Table: 239P
| Diabetes | Anaemia | Hypertension | |
| Metastatic (N=618) | 4.7% | 8.3% | 10.7% |
| Non-metastatic (N=4284) | 2.9% | 6.7% | 11.5% |
| p value | 0.015 | 0.141 | 0.567 |
| Hormonal positive (N=2658) | 2.6% | 6.1% | 11.5% |
| Hormonal negative (N=794) | 2.8% | 8.1% | 9.1% |
| p value | 0.742 | 0.049 | 0.053 |
| HER2+ (N=999) | 3.5% | 7.4% | 10.9% |
| HER2-(N=1834) | 2.1% | 6.5% | 9.5% |
| p value | 0.022 | 0.354 | 0.246 |
Conclusions
Diabetes, anaemia and hypertension are among the well known comorbidities of breast cancer patients. An analysis from patients’ reported data showed significant correlations between some of these comorbidities and metastatic, hormonal receptor and HER2 status. Although prospective studies are required to confirm correlation or causality, these findings may substantially contribute towards treatment planning for this group of cancer patients.
Legal entity responsible for the study
Care Across Ltd.
Funding
Has not received any funding.
Disclosure
P.A. Kosmidis: Personal, Other, Registration for conference: MSD, Sanofi, Pfizer; Personal, Other, Investigator meetings: Bristol Myers Squibb, LEO Pharma, Novartis. All other authors have declared no conflicts of interest.